These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Paliperidone Palmitate-Associated Severe Refractory Tardive Dyskinesia With Tardive Dystonia: Management and Six-Months Follow-Up. Singh S; Gupta A; Kuppili PP; Pattanayak RD; Khandelwal SK J Clin Psychopharmacol; 2016 Aug; 36(4):391-3. PubMed ID: 27269958 [No Abstract] [Full Text] [Related]
3. Drugs for psychotic disorders. Med Lett Drugs Ther; 2016 Dec; 58(1510):160-164. PubMed ID: 27960194 [No Abstract] [Full Text] [Related]
4. A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic. Lai JK; Margolese HC Schizophr Res; 2019 Feb; 204():443-444. PubMed ID: 30241989 [No Abstract] [Full Text] [Related]
5. Efficacy and safety of combined paliperidone palmitate and olanzapine pamoate in resistant schizoaffective disorder. Legrand G; Andrianarisoa M; Mauvieux J; Jalenques I J Clin Psychopharmacol; 2014 Oct; 34(5):652-3. PubMed ID: 25006816 [No Abstract] [Full Text] [Related]
6. Paliperidone Injection-Associated Delayed-Onset Rash. Sundling K; Held J; Narang P; Lippmann S Prim Care Companion CNS Disord; 2019 Jan; 21(1):. PubMed ID: 30817863 [No Abstract] [Full Text] [Related]
7. A case of tardive dystonia associated with long-acting injectable paliperidone palmitate. Ma CH; Chien YL; Liu CC; Chen IM; Lin CH Eur Neuropsychopharmacol; 2016 Jul; 26(7):1251-2. PubMed ID: 27130697 [No Abstract] [Full Text] [Related]
8. Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery. Williams W; McKinney C; Martinez L; Benson C J Med Econ; 2016; 19(5):469-76. PubMed ID: 26671481 [TBL] [Abstract][Full Text] [Related]
9. The importance of clinical observation: A case of subtle tardive dyskinesia with paliperidone palmitate. Omer HM; Thompson AD Aust N Z J Psychiatry; 2018 May; 52(5):496-497. PubMed ID: 29338294 [No Abstract] [Full Text] [Related]
10. Oral Facial Dystonia (Meige or Brueghel Syndrome) Induced by Paliperidone Palmitate. Marques JG Prim Care Companion CNS Disord; 2017 Jan; 19(1):. PubMed ID: 28129491 [No Abstract] [Full Text] [Related]
11. Late-onset Neuroleptic Malignant Syndrome Associated With Paliperidone Long-acting Injection and Lithium: A Case Report. Netcheva Z; Shin K J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):333-335. PubMed ID: 33605644 [No Abstract] [Full Text] [Related]
12. Lithium carbonate as a treatment for paliperidone extended-release-induced leukopenia and neutropenia in a patient with schizoaffective disorder; a case report. Matsuura H; Kimoto S; Harada I; Naemura S; Yamamuro K; Kishimoto T BMC Psychiatry; 2016 May; 16():161. PubMed ID: 27229149 [TBL] [Abstract][Full Text] [Related]
13. Use of Paliperidone Palmitate Throughout a Schizoaffective Disorder Patient's Gestation Period. Zamora Rodríguez FJ; Benítez Vega C; Sánchez-Waisen Hernández MR; Guisado Macías JA; Vaz Leal FJ Pharmacopsychiatry; 2017 Jan; 50(1):38-40. PubMed ID: 27414740 [No Abstract] [Full Text] [Related]
14. Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder. Joshi K; Lin J; Lingohr-Smith M; Fu DJ J Med Econ; 2015; 18(8):629-36. PubMed ID: 25800457 [TBL] [Abstract][Full Text] [Related]
15. Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety. Morris MT; Tarpada SP Psychopharmacol Bull; 2017 May; 47(2):42-52. PubMed ID: 28626271 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study. Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570 [TBL] [Abstract][Full Text] [Related]
17. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study. Bioque M; Parellada E; García-Rizo C; Amoretti S; Fortea A; Oriolo G; Palau P; Boix-Quintana E; Safont G; Bernardo M Eur Psychiatry; 2020 Jul; 63(1):e71. PubMed ID: 32669145 [TBL] [Abstract][Full Text] [Related]
18. Postinjection Delirium/Sedation Syndrome After Paliperidone Palmitate Injection in a Bipolar Affective Disorder Patient: A Case Report. Olguner Eker Ö; Turan T; Sarilar AC; Danaci Sezgin Sİ J Clin Psychopharmacol; 2024 May-Jun 01; 44(3):319-321. PubMed ID: 38656231 [No Abstract] [Full Text] [Related]
19. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence. Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266 [TBL] [Abstract][Full Text] [Related]
20. Olanzapine as a possible replacement choice for paliperidone-induced Pisa syndrome: a case report. Tsou CC; Huang SY Australas Psychiatry; 2016 Dec; 24(6):545-547. PubMed ID: 27590078 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]